Forecast
Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional
Food and Drug Administration
AI Overview
This FDA funding opportunity seeks development of physiologically-based pharmacokinetic (PBPK) modeling and mechanistic in vitro-in vivo correlation (IVIVC) approaches for long-acting injectable suspensions and implants. The research aims to improve drug development efficiency and regulatory decision-making for complex formulations.
This summary is AI-generated from the official solicitation.
Key Details
Agency
Food and Drug Administration
Funding Amount
—
Release Date
November 21, 2023
Due Date
—
Similar Opportunities
Active
Generative Unconstrained Intelligence Drug Engineering (GUIDE) collaboration between U.S. interagency, academic and industry partners
Due October 18, 2028
ActiveUniversal Cell Culture Platform for Rapid Establishment of Species-Agnostic Cell Lines and Autonomous Culture Operations
Due September 23, 2026
Get Alerts for Opportunities Like This
RallyProp monitors thousands of funding sources and sends instant alerts when opportunities match your technology and capabilities.
Start Free Trial